ArticleMedicine2026
Omentin-1 Val109Asp polymorphism and increased coronary artery disease risk in smokers with type 2 diabetes.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omentin-1 protein has protective effects against coronary artery disease (CAD). The Val109Asp polymorphism (rs2274907) in the Omentin-1 gene has been associated with CAD risk, but this relationship has not been investigated in patients with type 2 diabetes mellitus (T2DM). To investigate the association between the Omentin-1 Val109Asp polymorphism and CAD risk in Han Chinese patients with T2DM. This case-control study enrolled 465 Han Chinese patients with T2DM from July 2008 to September 2015. Participants were classified as CAD-positive (coronary stenosis > 50% in at least 1 major vessel, n = 249) or CAD-negative (n = 216). The Val109Asp polymorphism was genotyped using PCR-RFLP. Logistic regression analysis was performed to assess the association between genotypes and CAD risk, with adjustment for potential confounders including age, sex, smoking status, hypertension, dyslipidemia, diabetes duration, body mass index, and fasting glucose. The A allele frequency was higher in CAD patients than in controls (34.5% vs 27.5%; OR = 1.386; P = .026). Under the dominant model, TA/AA carriers had increased CAD risk compared with TT homozygotes (adjusted OR = 1.509, 95% CI: 1.025-2.222; P = .037). Stratified analyses showed that smokers carrying the A allele exhibited further elevated CAD risk (adjusted OR = 1.82, 95% CI: 1.02-3.27). The Omentin-1 Val109Asp polymorphism is associated with increased CAD risk in Han Chinese patients with T2DM under the dominant genetic model. Stratified findings suggest that smoking may further heighten CAD susceptibility among A-allele carriers. Integrating genetic and lifestyle factors may improve cardiovascular risk assessment in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.